![]() ![]() ![]() He is an internationally recognized expert in proton therapy for thoracic malignancies and reirradiation. Simone, II, MD, FACRO is Research Professor and Chief Medical Officer of New York Proton Center and Full Member in Radiation Oncology at Memorial Sloan Kettering. (3) Lessons learned from clinical trials of combination therapy, and what are the emerging opportunities for immune-RT combinations? ![]() (2) What is the recent development in immunotherapy including and beyond checkpoint blockade? (1) Are all radiation modalities the same? What is the recent development in radiotherapy? In this webinar, professor Simone provided insights into the following timely and critical topics. Professor Charles Simone is the national Principal Investigator of the SWOG/NRG Oncology intergroup trial combining immunotherapy and SBRT for early-stage non-small cell lung cancer and has led or been involved in several additional trials combining immune checkpoint inhibitors with radiation therapy. However, combining radiotherapy with immunotherapy has not been widely adapted due to clinical and regulatory challenges. A wealth of preclinical data suggested that radiotherapy synergizes with immunotherapy through several mechanisms, including enhancing tumor antigen release and presentation as well as promoting immune cell activation and infiltration. However, less than 20% of patients respond to any given immunotherapy, and acquired resistance is common. Immunotherapy is becoming the first-line therapy for an increasing number of cancer types. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |